- In-licensed oral calpain inhibitor KIO-401 completed Phase 3 trials in CRAO in Japan
- Multinational Phase 3 registration trial planned for initiation in 2027
- Expansion into Phase 2b for NAION targeted for 2028 subject to funding
?? Positive AI Sentiment (+4.5 / 10)